BioCryst Pharmaceuticals Inc

BioCryst insider buying signals confidence in its rare‑disease pipeline and new commercial strategy, but investors should weigh earnings volatility and regulatory risks.

BioCryst insider Dullinger’s large, conservative stake shows confidence amid executive sales, volatility, and cash‑flow challenges—watch key milestones for value.